HRP20161371T1 - Modulatori farmakokinetičkih svojstava terapeutika - Google Patents
Modulatori farmakokinetičkih svojstava terapeutika Download PDFInfo
- Publication number
- HRP20161371T1 HRP20161371T1 HRP20161371TT HRP20161371T HRP20161371T1 HR P20161371 T1 HRP20161371 T1 HR P20161371T1 HR P20161371T T HRP20161371T T HR P20161371TT HR P20161371 T HRP20161371 T HR P20161371T HR P20161371 T1 HRP20161371 T1 HR P20161371T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- radical
- denotes
- formula
- pharmaceutical formulation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 3
- 150000001875 compounds Chemical class 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims 12
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 12
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 claims 4
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims 4
- 229960003804 efavirenz Drugs 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 claims 4
- 229960004742 raltegravir Drugs 0.000 claims 4
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims 4
- 229960002814 rilpivirine Drugs 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 claims 2
- 229960004946 tenofovir alafenamide Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 1
- 101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 claims 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 1
- 229960003205 adefovir dipivoxil Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Claims (12)
1. Farmaceutska formulacija koja sadrži spoj formule IIB:
[image]
ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, naznačene time, što:
R10a i R10b nezavisno označavaju H ili -C1-4 alkil radikal;
R12 označava H ili -CH3 radikal;
R13 označava -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O)NR20R21, -(CH2)1-3C(O)R22, -(CH2)1-3S(O)2R22 ili -(CH2)1-3-R23 radikal;
R14 i R15 nezavisno označavaju H, -C1-4 alkil ili arilalkil radikal;
R17 i R18 nezavisno označavaju H ili -C1-3 alkil radikal;
R19 označava H, -C1-4 alkil ili arilalkil radikal;
R20 i R21 nezavisno označavaju H, -C1-3 alkil, -C(O)R17 ili S(O)2R17 radikal; ili
R20 i R21, zajedno sa atomom azota za koji su vezani, obrazuju nesupstituirani ili supstituirani heterociklični prsten s 5-6 članova koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O;
R22 označava H, -C1-3alkil, -OR19 ili -NR20R21 radikal; i
R23 označava nesupstituiran ili supstituiran heterociklični prsten s 5-6 članova koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O;
i što su navedeni nesupstituirani ili supstituirani heterociklični prsten s 5-6 članova oblikovani od strane R20 i R21 i naveden nesupstituiran ili supstituiran heterociklični prsten s 5-6 članova oblikovan od R23, nezavisno nesupstituirani ili supstituirani s C1-2 alkil radikalom,
koja dalje sadrži farmaceutski prihvatljiv nosač ili ekscipijens i najmanje jedan dodatni terapijski agens izabran iz grupe koju čine nukleotidni inhibitori HIV reverzne transkriptaze.
2. Farmaceutska formulacija prema patentnom zahtjevu 1 koja sadrži spoj formule IIB ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, naznačene time, što R13 označava -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O)NR20R21 ili -(CH2)1-3-R23 radikal.
3. Farmaceutska formulacija prema patentnom zahtjevu 2 koja sadrži spoj formule IIB ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, naznačene time, što R13 označava -(CH2)0-3CR17R18NR20R21 ili -(CH2)0-3CR17R18NR17C(O)NR20R21 radikal.
4. Farmaceutska formulacija prema patentnom zahtjevu 1, naznačena time, što spoj formule IIB označava spoj formule IIC:
[image]
ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, naznačene time, što:
R13 označava -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O)NR20R21, -(CH2)1-3C(O)R22 ili -(CH2)1-3-R23 radikal;
R17 i R18 nezavisno označavaju H ili C1-3 alkil radikal;
R19 označava H, -C1-4 alkil ili arilalkil radikal;
R20 i R21 nezavisno označavaju H, -C1-3 alkil, -C(O)R17 ili S(O)2R17 radikal; ili
R20 i R21, zajedno s atomom dušika za koji su vezani, formiraju heterociklični prsten s 5-6 članova koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O;
R22 označava H, -C1-3alkil, -OR19 ili -NR20R21 radikal; i
R23 označava nesupstituiran ili supstituiran heterociklični prsten s 5-6 članova koji sadrži 1-2 heteroatoma izabrana iz grupe koju čine N i O.
5. Farmaceutska formulacija prema patentnom zahtjevu 1, naznačena time, što spoj formule IIB označava spoj formule IIBa:
[image]
ili njegovu farmaceutski prihvatljivu sol, solvat i/ili ester.
6. Farmaceutska formulacija prema patentnom zahtjevu 1, naznačena time, što spoj formule IIB označava spoj formule IIBb:
[image]
(IIBb)
ili njegovu farmaceutski prihvatljivu sol, solvat i/ili ester.
7. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačena time, što se najmanje jedan dodatni terapijski agens metabolizira djelovanjem citokroma P450 monooksigenaze.
8. Farmaceutska formulacija prema bilo kojem od patentnih zahtjeva od 1 do 7, naznačena time, što su navedeni nukleotidni inhibitori HIV reverzne transkriptaze izabrani iz grupe koju čine tenofovir dizoproksil fumarat, adefovir dipivoksil i GS-7340.
9. Farmaceutska formulacija prema patentnom zahtjevu 8, naznačena time, što navedeni nukleotidni inhibitor HIV reverzne transkriptaze označava tenofovir dizoproksil fumarat.
10. Farmaceutska formulacija prema patentnom zahtjevu 8, naznačena time, što navedeni nukleotidni inhibitor HIV reverzne transkriptaze označava GS-7340.
11. Farmaceutska formulacija prema patentnom zahtjevu 10, naznačena time, što sadrži kombinaciju izabranu iz grupe koju čine:
spoj formule IIBb/tenofovir dizoproksil fumarat/GS-9131,
spoj formule IIBb/tenofovir dizoproksil fumarat/efavirenc,
spoj formule IIBb/tenofovir dizoproksil fumarat/raltegravir i
spoj formule IIBb/tenofovir dizoproksil fumarat/rilpivirin.
12. Farmaceutska formulacija prema patentnom zahtjevu 9, naznačena time, što sadrži kombinaciju izabranu iz grupe koju čine:
spoj formule IIBb/tenofovir dizoproksil fumarat/GS-9131/efavirenc,
spoj formule IIBb/tenofovir dizoproksil fumarat/GS-9131/raltegravir,
spoj formule IIBb/tenofovir dizoproksil fumarat/GS-9131/rilpivirin,
spoj formule IIBb/tenofovir dizoproksil fumarat/efavirenc/raltegravir,
spoj formule IIBb/tenofovir dizoproksil fumarat/efavirenc/rilpivirin i
spoj formule IIBb/tenofovir dizoproksil fumarat/raltegravir/rilpivirin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90322807P | 2007-02-23 | 2007-02-23 | |
US95871607P | 2007-07-06 | 2007-07-06 | |
EP12167596.1A EP2487166B1 (en) | 2007-02-23 | 2008-02-22 | Modulators of pharmacokinetic properties of therapeutics |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20161371T1 true HRP20161371T1 (hr) | 2016-12-02 |
Family
ID=39522375
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161371TT HRP20161371T1 (hr) | 2007-02-23 | 2016-10-20 | Modulatori farmakokinetičkih svojstava terapeutika |
HRP20161428TT HRP20161428T1 (hr) | 2007-02-23 | 2016-11-02 | Modulatori farmakokinetičkih svojstava lijekova |
HRP20161476TT HRP20161476T1 (hr) | 2007-02-23 | 2016-11-08 | Modulatori farmakokinetičkih svojstava lijekova |
HRP20161502TT HRP20161502T1 (hr) | 2007-02-23 | 2016-11-14 | Modulatori farmakokinetičkih svojstava lijekova |
HRP20200349TT HRP20200349T1 (hr) | 2007-02-23 | 2020-03-02 | Modulatori farmakokinetičkih osobina terapeutika |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20161428TT HRP20161428T1 (hr) | 2007-02-23 | 2016-11-02 | Modulatori farmakokinetičkih svojstava lijekova |
HRP20161476TT HRP20161476T1 (hr) | 2007-02-23 | 2016-11-08 | Modulatori farmakokinetičkih svojstava lijekova |
HRP20161502TT HRP20161502T1 (hr) | 2007-02-23 | 2016-11-14 | Modulatori farmakokinetičkih svojstava lijekova |
HRP20200349TT HRP20200349T1 (hr) | 2007-02-23 | 2020-03-02 | Modulatori farmakokinetičkih osobina terapeutika |
Country Status (31)
Country | Link |
---|---|
US (7) | US8148374B2 (hr) |
EP (4) | EP2487161B1 (hr) |
JP (9) | JP4881446B2 (hr) |
KR (2) | KR101577698B1 (hr) |
CN (2) | CN103435570B (hr) |
AP (2) | AP2986A (hr) |
AR (1) | AR065439A1 (hr) |
AU (1) | AU2008218186C1 (hr) |
BR (1) | BRPI0807581A2 (hr) |
CA (1) | CA2678907C (hr) |
CY (9) | CY1118292T1 (hr) |
DK (2) | DK3150586T3 (hr) |
EA (1) | EA019893B1 (hr) |
ES (6) | ES2601820T3 (hr) |
FR (1) | FR20C1021I1 (hr) |
HK (1) | HK1137451A1 (hr) |
HR (5) | HRP20161371T1 (hr) |
HU (6) | HUE031707T2 (hr) |
IL (1) | IL200550A0 (hr) |
LT (9) | LT3150586T (hr) |
LU (1) | LUC00156I2 (hr) |
MX (1) | MX2009008935A (hr) |
NO (4) | NO2017001I1 (hr) |
NZ (1) | NZ579802A (hr) |
PL (3) | PL3150586T3 (hr) |
PT (6) | PT2487162T (hr) |
SG (2) | SG10201705929QA (hr) |
SI (1) | SI3150586T1 (hr) |
TW (1) | TWI533868B (hr) |
WO (1) | WO2008103949A1 (hr) |
ZA (1) | ZA200905882B (hr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1628685T3 (pl) | 2003-04-25 | 2011-05-31 | Gilead Sciences Inc | Przeciwwirusowe analogi fosfonianowe |
DK1778251T3 (da) | 2004-07-27 | 2011-07-18 | Gilead Sciences Inc | Nukleosidphosphatkonjugater som anti-HIV-midler |
RS54237B9 (sr) * | 2006-07-07 | 2019-07-31 | Gilead Sciences Inc | Modulatori farmakokinetičkih svojstava terapeutika |
EP2465856A3 (en) * | 2006-08-31 | 2012-12-12 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
SI2487161T1 (sl) | 2007-02-23 | 2016-12-30 | Gilead Sciences, Inc. | Modulatorji farmakokinetičnih lastnosti terapevtikov |
PL3150586T3 (pl) | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
WO2009067225A2 (en) * | 2007-11-20 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Boceprevir derivatives for the treatment of hcv infections |
JP5629585B2 (ja) * | 2008-01-04 | 2014-11-19 | ギリアード サイエンシーズ, インコーポレイテッド | シトクロムp450のインヒビター |
EA201591353A1 (ru) * | 2008-05-02 | 2016-01-29 | Джилид Сайэнс, Инк. | Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента |
CN102089318B (zh) | 2008-07-08 | 2014-05-21 | 吉里德科学公司 | Hiv抑制剂化合物的盐 |
PL2364314T3 (pl) | 2008-12-09 | 2014-08-29 | Gilead Sciences Inc | Modulatory receptorów Toll-podobnych |
BRPI1008664A2 (pt) | 2009-02-06 | 2016-03-08 | Gilead Sciences Inc | comprimidos para a terapia de combinação |
AU2015200637C1 (en) * | 2009-02-06 | 2017-08-03 | Gilead Sciences, Inc. | Tablets for combination therapy |
UA108738C2 (uk) * | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
WO2010151672A2 (en) * | 2009-06-26 | 2010-12-29 | Georgetown University | Amino acid derived ureas |
EP3351249A1 (en) | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
NL2005306C2 (nl) * | 2010-09-02 | 2012-03-05 | Tersia Nederland B V | Koppelstuk voor meerlaagse leidingen, lasapparaaat voor het verbinden van het koppelstuk met meerlaagse leidingen, werkwijze van koppelen en een samenstel verkregen via de werkwijze. |
WO2012045007A1 (en) | 2010-10-01 | 2012-04-05 | Gilead Sciences, Inc. | Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester |
EP2826466A1 (en) * | 2010-11-19 | 2015-01-21 | Gilead Sciences, Inc. | Therapeutic compositions comprising rilpivirin hcl and tenofovir disoproxil fumarate |
WO2012088156A1 (en) | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
WO2012088153A1 (en) * | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
WO2012088178A1 (en) | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
EP2472320A2 (en) | 2010-12-30 | 2012-07-04 | Rohm and Haas Electronic Materials LLC | Compositions comprising base-reactive component and processes for photolithography |
EP2705027B1 (en) * | 2011-05-02 | 2015-06-03 | Gilead Sciences, Inc. | Amorphous solid salts of Cobicistat (GS-9350) |
JP6122427B2 (ja) | 2011-07-07 | 2017-04-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ダルナビル複合製剤 |
HRP20161696T4 (hr) | 2011-08-16 | 2023-10-13 | Gilead Sciences, Inc. | Tenofovir alafenamid hemifumarat |
CA2863662A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
AU2012327170A1 (en) * | 2012-02-03 | 2013-08-22 | Gilead Sciences, Inc. | Therapeutic compounds |
MX2014009344A (es) | 2012-02-03 | 2015-05-11 | Gilead Sciences Inc | Metodos e intermediarios para preparar agentes farmaceuticos. |
CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
WO2014057498A2 (en) | 2012-10-08 | 2014-04-17 | Mylan Laboratories Ltd. | Process for the preparation of cobicistat intermediates |
CN104884063A (zh) * | 2012-10-23 | 2015-09-02 | 西普拉有限公司 | 抗逆转录病毒药物组合物 |
SI3608325T1 (sl) | 2012-12-21 | 2022-09-30 | Gilead Sciences, Inc. | Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba |
JP2016504364A (ja) | 2012-12-26 | 2016-02-12 | アッシア・ケミカル・インダストリーズ・リミテッド | コビシスタット塩 |
WO2015006731A1 (en) | 2013-07-12 | 2015-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
NO2865735T3 (hr) | 2013-07-12 | 2018-07-21 | ||
EP3421033B1 (en) | 2013-10-07 | 2022-07-27 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Hiv treatment formulation of atazanavir and cobicistat |
WO2015083066A1 (en) | 2013-12-03 | 2015-06-11 | Mylan Laboratories Ltd. | Preparation of cobicistat intermediates |
WO2015145324A1 (en) | 2014-03-25 | 2015-10-01 | Mylan Laboratories Ltd | Process for the preparation of cobicistat |
NO2717902T3 (hr) | 2014-06-20 | 2018-06-23 | ||
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
AU2015287773B2 (en) | 2014-07-11 | 2018-03-29 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
CR20170061A (es) * | 2014-07-17 | 2017-07-17 | Chdi Foundation Inc | Métodos y composiciones para el tratamiento de trastornos relacionados con vih |
EP3194401B1 (en) | 2014-09-16 | 2020-10-21 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
US20190022116A1 (en) | 2014-12-26 | 2019-01-24 | Emory University | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto |
ES2837383T3 (es) | 2015-04-02 | 2021-06-30 | Gilead Sciences Inc | Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica |
CN105198829B (zh) * | 2015-08-15 | 2017-10-31 | 浙江永宁药业股份有限公司 | 一种可比司他中间体的制备方法及其中间体和用途 |
CN107513046B (zh) * | 2016-06-15 | 2019-12-13 | 江苏欧信制药有限公司 | 一种可比司他的合成方法 |
JP6764017B2 (ja) * | 2016-08-04 | 2020-09-30 | ギリアード サイエンシーズ, インコーポレイテッド | がんの処置での使用のためのコビシスタット |
BR112019002132A2 (pt) | 2016-08-08 | 2019-05-14 | Hetero Labs Limited | composições anti-retrovirais |
EP3496719B1 (en) | 2016-08-08 | 2023-06-14 | Hetero Labs Limited | A multi-class anti-retroviral composition |
KR101908853B1 (ko) * | 2017-05-17 | 2018-10-16 | 경북대학교 산학협력단 | 아세틸시코닌을 유효성분으로 함유하는 시토크롬 p450 동효소 억제용 조성물 |
PT3661937T (pt) | 2017-08-01 | 2021-09-24 | Gilead Sciences Inc | Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais |
CA3082191C (en) | 2017-12-07 | 2021-09-21 | Emory University | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN109912530A (zh) * | 2017-12-13 | 2019-06-21 | 上海奥博生物医药技术有限公司 | 一种可比司他原料杂质的制备方法 |
CN111989316B (zh) * | 2018-01-30 | 2023-09-08 | 潘贝拉治疗股份有限公司 | 用于生产(6s,15s)-3,8,13,18-四氮杂二十烷-6,15-二醇的方法 |
WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
CN117105928B (zh) * | 2023-08-22 | 2024-03-26 | 上海蓝木化工有限公司 | 一种蛋白酶抑制剂及其制备方法 |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US77295A (en) * | 1868-04-28 | theqdoee krausch | ||
US115665A (en) * | 1871-06-06 | Improvement in folding-steps for carriages | ||
US199851A (en) * | 1878-01-29 | Improvement in circular saws | ||
US191319A (en) * | 1877-05-29 | Improvement in stoves | ||
US108617A (en) * | 1870-10-25 | Improvement in ore-pulverizers | ||
US127689A (en) * | 1872-06-11 | Improvement in differential pulley-blocks | ||
US143314A (en) * | 1873-09-30 | Improvement in condenser-tube fastenings | ||
US181902A (en) * | 1876-09-05 | Improvement in bell toys | ||
US99902A (en) * | 1870-02-15 | 1870-02-15 | Improvement in adjustable dials for travelers watches | |
US3400197A (en) | 1965-01-26 | 1968-09-03 | Robins Co Inc A H | Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules |
US3882114A (en) | 1967-10-26 | 1975-05-06 | Oreal | N-(morpholinomethyl carbamyl) cysteamine and glycine |
GB1241024A (en) | 1968-10-29 | 1971-07-28 | Boehringer Sohn Ingelheim | Pharmaceutical tablet base and a process for its manufacture |
CA926708A (en) | 1970-06-15 | 1973-05-22 | Oushima Yoshitaka | Process for producing spherical pellets |
GB1339764A (en) | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
CH586568A5 (hr) | 1972-04-10 | 1977-04-15 | Hoffmann La Roche | |
US3957774A (en) | 1972-04-17 | 1976-05-18 | L'oreal | N-morpholinomethyl-n-'-substituted ethyl and propylureas |
DE2845326C2 (de) | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
HU186777B (en) | 1981-07-09 | 1985-09-30 | Magyar Tudomanyos Akademia | Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them |
US4603143A (en) | 1983-05-02 | 1986-07-29 | Basf Corporation | Free-flowing, high density, fat soluble vitamin powders with improved stability |
GB8413191D0 (en) | 1984-05-23 | 1984-06-27 | Beecham Group Plc | Pharmaceutical composition |
FR2631620B1 (fr) | 1988-05-19 | 1990-07-27 | Rhone Poulenc Chimie | Nouvelle silice precipitee absorbante et composition a base de cette s ilice |
US5362912A (en) | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
EP0428849A3 (en) | 1989-09-28 | 1991-07-31 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
IE913840A1 (en) * | 1990-11-20 | 1992-05-20 | Abbott Lab | Retroviral protease inhibiting compounds |
GB9109862D0 (en) | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
JPH06127981A (ja) | 1992-03-03 | 1994-05-10 | Fuainiteii Kk | 複合複層ガラス及びそれを使用した窓 |
US5968942A (en) * | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
ES2317977T3 (es) | 1992-12-29 | 2009-05-01 | Abbott Laboratories | Procedimientos e intermediarios para la preparacion de inhibidores de proteasa retrovirales. |
WO1995005808A1 (en) | 1993-08-24 | 1995-03-02 | Abbott Laboratories | Oil-based tableting method |
US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5567823A (en) | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5763464A (en) | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
JP4064476B2 (ja) | 1996-03-29 | 2008-03-19 | エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド | 二酸化珪素を有する球状凝集した澱粉 |
US6348216B1 (en) | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5939090A (en) | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
JP4494539B2 (ja) | 1997-02-28 | 2010-06-30 | ディーエスエム アイピー アセッツ ビー.ブイ. | 流動自由な乾燥粒子 |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
FR2767071B1 (fr) | 1997-08-06 | 1999-09-10 | Rhodia Chimie Sa | Composition comprenant un liquide absorbe sur un support a base de silice precipitee |
AU2010299A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
FR2773994B1 (fr) | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
JP4027535B2 (ja) | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂溶性薬物を含有した粉末 |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
CA2371109C (en) * | 1999-06-04 | 2011-04-26 | Laman A. Alani | Improved pharmaceutical formulations |
WO2001025240A1 (en) | 1999-10-06 | 2001-04-12 | Tibotec Pharmaceuticals Ltd. | HEXAHYDROFURO'2,3-B!FURAN-3-YL-N- {3'(1,3-BENZODIOXOL -5- YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL} CARBAMATE AS RETROVIRAL PROTEASE INHIBITOR |
CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
US6448245B1 (en) | 2000-05-04 | 2002-09-10 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of and compounds for inhibiting calpains |
US20030035834A1 (en) | 2000-05-26 | 2003-02-20 | Pawan Seth | Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release |
JPWO2002024167A1 (ja) | 2000-09-19 | 2004-01-29 | 第一製薬株式会社 | 医薬組成物 |
US7056951B2 (en) | 2000-09-26 | 2006-06-06 | Mutual Pharmaceutical Co., Inc. | Stable solid dosage forms of amino acids and processes for producing same |
US6524615B2 (en) | 2001-02-21 | 2003-02-25 | Kos Pharmaceuticals, Incorporated | Controlled release pharmaceutical composition |
DE10112651A1 (de) | 2001-03-16 | 2002-09-19 | Degussa | Inhomogene Kieselsäuren als Trägermaterial |
AP2003002900A0 (en) | 2001-05-01 | 2003-12-31 | Pfizer Prod Inc | Method for manufacturing a low dose pharmaceutical composition |
DE10126163A1 (de) | 2001-05-30 | 2002-12-05 | Degussa | Pharmazeutische Zubereitungen |
ES2739852T3 (es) | 2001-07-06 | 2020-02-04 | Veloxis Pharmaceuticals As | Aglomeración controlada |
US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
US7815936B2 (en) | 2001-10-30 | 2010-10-19 | Evonik Degussa Gmbh | Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
AU2002219964A1 (en) | 2001-11-29 | 2003-06-17 | Penwest Pharmaceutical Company | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
US20030206978A1 (en) | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
US7285566B2 (en) | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
EP1467970B1 (en) | 2002-01-17 | 2007-08-22 | Merck & Co., Inc. | Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
US6926906B2 (en) | 2002-02-20 | 2005-08-09 | M./S. Strides, Inc. | Orally administrable pharmaceutical formulation |
US6726448B2 (en) | 2002-05-15 | 2004-04-27 | General Electric Company | Ceramic turbine shroud |
PA8576201A1 (es) | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
DE10250711A1 (de) | 2002-10-31 | 2004-05-19 | Degussa Ag | Pharmazeutische und kosmetische Zubereitungen |
PE20040840A1 (es) | 2002-11-20 | 2004-12-30 | Japan Tobacco Inc | Derivados de 4-oxoquinolina como inhibidores de la integrasa del vih |
US7189416B2 (en) | 2002-11-23 | 2007-03-13 | Glykon Technologies Group, Llc | Method for stable and controlled delivery of (-)-hydroxycitric acid |
JP2004184681A (ja) | 2002-12-03 | 2004-07-02 | Konica Minolta Holdings Inc | 熱現像感光材料 |
CA2512319A1 (en) | 2003-01-14 | 2004-08-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
EP1596835A1 (en) | 2003-02-19 | 2005-11-23 | H. Lundbeck A/S | Method for preparation of an agglomerate using melt agglomeration |
FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
JP4018664B2 (ja) | 2003-04-30 | 2007-12-05 | 第一三共株式会社 | 安定化固形製剤 |
DE10337198A1 (de) | 2003-08-13 | 2005-03-17 | Degussa Ag | Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind |
US20050048112A1 (en) | 2003-08-28 | 2005-03-03 | Jorg Breitenbach | Solid pharmaceutical dosage form |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
JP2005075826A (ja) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Internatl Gmbh | 多孔質シリカ担体を含有する徐放性製剤 |
JP2005091988A (ja) | 2003-09-19 | 2005-04-07 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料及び画像形成方法 |
EP1675576A1 (en) | 2003-10-03 | 2006-07-05 | LifeCycle Pharma A/S | A method for preparing modified release pharmaceutical compositions |
US20050096390A1 (en) | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and pravastatin |
US20050095287A1 (en) | 2003-10-29 | 2005-05-05 | Matharu Amol S. | Fosinopril composition |
US7834043B2 (en) | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
WO2005084670A1 (en) | 2004-03-01 | 2005-09-15 | Lek Pharmaceuticals D.D. | Pharmaceutical formulation |
MY142989A (en) | 2004-03-10 | 2011-02-14 | Bayer Schering Pharma Ag | Stabilised supersaturated solids of lipophilic drugs |
WO2005105040A2 (en) | 2004-04-26 | 2005-11-10 | Micelle Products, Inc. | Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications |
BRPI0401742B8 (pt) | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
EP1758581A1 (en) | 2004-05-21 | 2007-03-07 | Japan Tobacco, Inc. | Combinations comprising a 4-isoquinolone derivative and anti-hiv agents |
JP2006003701A (ja) | 2004-06-18 | 2006-01-05 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料および画像形成方法 |
EA013632B1 (ru) | 2004-06-28 | 2010-06-30 | Лайфсайкл Фарма А/С | Пористые таблетки в качестве носителей для жидких композиций |
US7718633B2 (en) * | 2004-07-06 | 2010-05-18 | Abbott Laboratories | Prodrugs of HIV protease inhibitors |
AR045841A1 (es) | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. |
CA2584670A1 (en) | 2004-10-19 | 2006-04-27 | Achillion Pharmaceuticals, Inc. | Combination therapy for treating viral infections |
US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
US20070014854A1 (en) | 2005-07-15 | 2007-01-18 | Ilan Zalit | Novel granulation process |
EP1978939A2 (en) | 2005-12-27 | 2008-10-15 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine |
SG170795A1 (en) | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
US20090233964A1 (en) | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
US20090186081A1 (en) | 2006-01-05 | 2009-07-23 | Lifecycle Pharma A/S | Disintegrating Loadable Tablets |
US20100285157A1 (en) | 2006-02-20 | 2010-11-11 | Asahi Breweries, Ltd | Granules, tablets and method of producing the same |
US20070287664A1 (en) | 2006-03-23 | 2007-12-13 | Schering Corporation | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto |
RS54237B9 (sr) | 2006-07-07 | 2019-07-31 | Gilead Sciences Inc | Modulatori farmakokinetičkih svojstava terapeutika |
CL2007002331A1 (es) | 2006-08-10 | 2008-04-18 | Cipla Ltd | Composicion oral solida que comprede uno o mas farmacos antirretrovirales y al menos un polimero insoluble en agua, en relacion aproximadamente 1:1 hasta 1:6; proceso de elaboracion; y uso para el tratamiento del vih. |
EP2465856A3 (en) | 2006-08-31 | 2012-12-12 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
US20090281132A1 (en) | 2006-09-04 | 2009-11-12 | Kiran Kumar Narsaiah Velaveni | Pharmaceutical formulation for use in hiv therapy |
US7749537B2 (en) | 2006-12-04 | 2010-07-06 | Scolr Pharma, Inc. | Method of forming a tablet |
PL3150586T3 (pl) | 2007-02-23 | 2020-06-01 | Gilead Sciences, Inc. | Modulatory farmakokinetycznych właściwości środków terapeutycznych |
WO2009006203A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
SG182229A1 (en) | 2007-06-29 | 2012-07-30 | Gilead Sciences Inc | Therapeutic compositions and the use thereof |
AU2008275744A1 (en) * | 2007-07-06 | 2009-01-15 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
BRPI0821700A2 (pt) | 2007-12-27 | 2015-06-16 | Baxter Int | Métodos para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína em um conjugado polímero-proteína e para determinar o número de moléculas de polímero fisiologicamente aceitáveis ligadas a uma proteína ou a um complexo de proteína ou livre em solução |
EA201591353A1 (ru) * | 2008-05-02 | 2016-01-29 | Джилид Сайэнс, Инк. | Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента |
BRPI1008664A2 (pt) | 2009-02-06 | 2016-03-08 | Gilead Sciences Inc | comprimidos para a terapia de combinação |
EP2238979A1 (en) | 2009-04-06 | 2010-10-13 | LEK Pharmaceuticals d.d. | Active pharmaceutical ingredient adsorbed on solid support |
WO2013105474A1 (ja) | 2012-01-10 | 2013-07-18 | Jnc株式会社 | 発光層用材料およびこれを用いた有機電界発光素子 |
CA2863662A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
-
2008
- 2008-02-22 PL PL16180589T patent/PL3150586T3/pl unknown
- 2008-02-22 AU AU2008218186A patent/AU2008218186C1/en active Active
- 2008-02-22 AP AP2009004964A patent/AP2986A/xx active
- 2008-02-22 ES ES12167589.6T patent/ES2601820T3/es active Active
- 2008-02-22 CA CA2678907A patent/CA2678907C/en active Active
- 2008-02-22 KR KR1020097019921A patent/KR101577698B1/ko active IP Right Grant
- 2008-02-22 MX MX2009008935A patent/MX2009008935A/es active IP Right Grant
- 2008-02-22 HU HUE12167589A patent/HUE031707T2/en unknown
- 2008-02-22 ES ES12167590.4T patent/ES2603617T3/es active Active
- 2008-02-22 TW TW097106375A patent/TWI533868B/zh active
- 2008-02-22 NZ NZ579802A patent/NZ579802A/en unknown
- 2008-02-22 EP EP12167589.6A patent/EP2487161B1/en active Active
- 2008-02-22 JP JP2009551044A patent/JP4881446B2/ja active Active
- 2008-02-22 LT LTEP16180589.0T patent/LT3150586T/lt unknown
- 2008-02-22 SG SG10201705929QA patent/SG10201705929QA/en unknown
- 2008-02-22 PT PT121675904T patent/PT2487162T/pt unknown
- 2008-02-22 LT LTEP12167591.2T patent/LT2487163T/lt unknown
- 2008-02-22 ES ES12167591.2T patent/ES2603645T3/es active Active
- 2008-02-22 HU HUE12167591A patent/HUE029843T2/en unknown
- 2008-02-22 PL PL12167590T patent/PL2487162T3/pl unknown
- 2008-02-22 CN CN201310326757.5A patent/CN103435570B/zh active Active
- 2008-02-22 WO PCT/US2008/054788 patent/WO2008103949A1/en active Application Filing
- 2008-02-22 EP EP16180589.0A patent/EP3150586B1/en active Active
- 2008-02-22 HU HUE12167596A patent/HUE029866T2/en unknown
- 2008-02-22 EA EA200901155A patent/EA019893B1/ru unknown
- 2008-02-22 CN CN2008800132554A patent/CN101679325B/zh active Active
- 2008-02-22 LT LTEP12167589.6T patent/LT2487161T/lt unknown
- 2008-02-22 US US12/036,124 patent/US8148374B2/en active Active
- 2008-02-22 EP EP19219599.8A patent/EP3689353A1/en active Pending
- 2008-02-22 PT PT87435319T patent/PT2118082E/pt unknown
- 2008-02-22 HU HUE12167590A patent/HUE029842T2/en unknown
- 2008-02-22 US US12/528,185 patent/US9891239B2/en active Active
- 2008-02-22 DK DK16180589.0T patent/DK3150586T3/da active
- 2008-02-22 KR KR1020157011742A patent/KR101664154B1/ko active IP Right Grant
- 2008-02-22 LT LTEP12167596.1T patent/LT2487166T/lt unknown
- 2008-02-22 SG SG2012054037A patent/SG183059A1/en unknown
- 2008-02-22 DK DK12167596.1T patent/DK2487166T3/en active
- 2008-02-22 LT LTEP12167590.4T patent/LT2487162T/lt unknown
- 2008-02-22 PT PT121675912T patent/PT2487163T/pt unknown
- 2008-02-22 AR ARP080100737A patent/AR065439A1/es not_active Application Discontinuation
- 2008-02-22 AP AP2013007042A patent/AP3915A/en active
- 2008-02-22 ES ES08743531.9T patent/ES2525454T3/es active Active
- 2008-02-22 PT PT121675961T patent/PT2487166T/pt unknown
- 2008-02-22 PT PT121675896T patent/PT2487161T/pt unknown
- 2008-02-22 SI SI200832112T patent/SI3150586T1/sl unknown
- 2008-02-22 PL PL12167589T patent/PL2487161T3/pl unknown
- 2008-02-22 ES ES12167596.1T patent/ES2602784T3/es active Active
- 2008-02-22 ES ES16180589T patent/ES2779826T3/es active Active
- 2008-02-22 PT PT161805890T patent/PT3150586T/pt unknown
- 2008-02-22 EP EP08743531.9A patent/EP2118082B1/en active Active
- 2008-02-22 BR BRPI0807581-6A2A patent/BRPI0807581A2/pt not_active Application Discontinuation
-
2009
- 2009-08-23 IL IL200550A patent/IL200550A0/en unknown
- 2009-08-25 ZA ZA2009/05882A patent/ZA200905882B/en unknown
-
2010
- 2010-04-28 HK HK10104142.7A patent/HK1137451A1/xx unknown
-
2011
- 2011-08-23 JP JP2011181974A patent/JP5554300B2/ja active Active
- 2011-11-21 US US13/301,642 patent/US8486942B2/en active Active
-
2013
- 2013-07-03 US US13/935,117 patent/US20140017199A1/en not_active Abandoned
-
2014
- 2014-02-13 JP JP2014025059A patent/JP2014088441A/ja not_active Withdrawn
- 2014-11-04 US US14/532,868 patent/US20150139948A1/en not_active Abandoned
-
2015
- 2015-01-28 JP JP2015013971A patent/JP6147282B2/ja active Active
- 2015-08-03 US US14/817,068 patent/US20160069915A1/en not_active Abandoned
-
2016
- 2016-04-05 JP JP2016075593A patent/JP6147388B2/ja active Active
- 2016-07-05 JP JP2016132990A patent/JP6192776B2/ja active Active
- 2016-10-20 HR HRP20161371TT patent/HRP20161371T1/hr unknown
- 2016-10-25 CY CY20161101075T patent/CY1118292T1/el unknown
- 2016-11-01 US US15/340,538 patent/US20170158647A1/en not_active Abandoned
- 2016-11-02 HR HRP20161428TT patent/HRP20161428T1/hr unknown
- 2016-11-08 HR HRP20161476TT patent/HRP20161476T1/hr unknown
- 2016-11-09 CY CY20161101152T patent/CY1118219T1/el unknown
- 2016-11-14 CY CY20161101168T patent/CY1118227T1/el unknown
- 2016-11-14 HR HRP20161502TT patent/HRP20161502T1/hr unknown
- 2016-11-15 CY CY20161101170T patent/CY1118232T1/el unknown
- 2016-12-12 HU HUS1600054C patent/HUS1600054I1/hu unknown
- 2016-12-16 LT LTPA2016039C patent/LTC2487163I2/lt unknown
- 2016-12-16 LT LTPA2016038C patent/LTC2487166I2/lt unknown
- 2016-12-16 LT LTPA2016040C patent/LTC2487162I2/lt unknown
-
2017
- 2017-01-04 CY CY2017002C patent/CY2017002I1/el unknown
- 2017-01-04 CY CY2017001C patent/CY2017001I1/el unknown
- 2017-01-04 CY CY2017003C patent/CY2017003I1/el unknown
- 2017-01-12 NO NO2017001C patent/NO2017001I1/no unknown
- 2017-01-12 NO NO2017002C patent/NO2017002I1/no unknown
- 2017-01-12 NO NO2017003C patent/NO2017003I1/no unknown
- 2017-07-11 JP JP2017135437A patent/JP2017171695A/ja not_active Withdrawn
-
2019
- 2019-01-17 JP JP2019006234A patent/JP2019059790A/ja not_active Withdrawn
-
2020
- 2020-03-02 HR HRP20200349TT patent/HRP20200349T1/hr unknown
- 2020-03-13 CY CY20201100220T patent/CY1122761T1/el unknown
- 2020-06-02 LU LU00156C patent/LUC00156I2/en unknown
- 2020-06-03 HU HUS2000013C patent/HUS2000013I1/hu unknown
- 2020-06-04 LT LTPA2020508C patent/LTC3150586I2/lt unknown
- 2020-06-05 NO NO2020011C patent/NO2020011I1/no unknown
- 2020-06-05 CY CY2020011C patent/CY2020011I1/el unknown
- 2020-06-17 FR FR20C1021C patent/FR20C1021I1/fr active Active
- 2020-10-08 JP JP2020170304A patent/JP2021001236A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20161371T1 (hr) | Modulatori farmakokinetičkih svojstava terapeutika | |
HRP20150744T2 (hr) | Modulatori farmakokinetiäśkih svojstava lijekova | |
WO2008148868A8 (en) | Piperidine/piperazine derivatives | |
JP2006524225A5 (hr) | ||
JP2016518434A5 (hr) | ||
HRP20220899T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba | |
RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
JP2016538313A5 (hr) | ||
JP2008525417A5 (hr) | ||
WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
JP2005531516A5 (hr) | ||
MX2009000871A (es) | Novedosos inhibidores de transcriptasa inversa de vih. | |
CY1116190T1 (el) | Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην | |
EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
WO2007138472A3 (en) | Triazolopyridazine derivatives | |
GEP20094605B (en) | Pyrazole derivatives, compositions containing such compounds and methods of use thereof | |
MX2009013832A (es) | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. | |
HRP20090593T1 (hr) | Derivati benzimidazola i njihova uporaba kao antagonista aii receptora | |
HUP0300148A2 (en) | Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them | |
TW200626145A (en) | Heterocyclic compounds and thrombopoietin receptor activators | |
WO2008147557A3 (en) | Heteroaryl substituted thiazoles and their use as antiviral agents | |
HK1146049A1 (en) | Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1 | |
TW200728298A (en) | Thiophene compounds and thrombopoietin receptor activators | |
GEP20237476B (en) | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors | |
MA34313B1 (fr) | Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan |